Key facts
- AllergyRhino’s last known valuation is $5.9M (Sep 2025).
- It has raised $470K; the latest was Early Stage VC ($470K) in Sep 2025.
- Notable investors include Lexham Capital Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AllergyRhino
- ·The full record, as it builds
Funding rounds
No funding rounds for AllergyRhino are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AllergyRhino
Provider of allergy care treatment and medicines intended to help people deal with allergies. The company offers allergen tablets, personalized sublingual immunotherapy treatment, allergy tests, and a pollen map, enabling adults and children suffering from allergies such as hay fever, food allergies, and pet allergies to control and relieve naturally by training their immune system and addressing the root cause of the allergies.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- allergyrhino.com/
- Ownership
- Privately Held (backing)
AllergyRhino doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AllergyRhino shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AllergyRhino in its N-PORT filings yet. We sweep new filings monthly.